Patents by Inventor Xile LIU

Xile LIU has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds containing benzosultam
    Patent number: 11718610
    Abstract: Disclosed is a class of compounds containing arylsultam, and specifically disclosed are a compound represented by formula (II), and a pharmaceutically acceptable salt or an isomer thereof.
    Type: Grant
    Filed: April 26, 2021
    Date of Patent: August 8, 2023
    Assignee: MEDSHINE DISCOVERY INC.
    Inventors: Xile Liu, Charles Z. Ding, Shuhui Chen, Lihong Hu, Haiwen Wan, Xiu Jiang
  • COMPOUNDS CONTAINING BENZOSULTAM
    Publication number: 20230183230
    Abstract: Disclosed is a class of compounds containing arylsultam, and specifically disclosed are a compound represented by formula (II), and a pharmaceutically acceptable salt or an isomer thereof.
    Type: Application
    Filed: April 26, 2021
    Publication date: June 15, 2023
    Inventors: Xile LIU, Charles Z. DING, Shuhui CHEN, Lihong HU, Haiwen WAN, Xiu JIANG
  • PYRIMIDINYL GROUP-CONTAINING TRICYCLIC COMPOUND SERVING AS C-MET INHIBITOR
    Publication number: 20230056559
    Abstract: Disclosed are a pyrimidinyl group-containing tricyclic compound and applications thereof in preparing a cancer-treating medicament. Specifically disclosed are a compound as represented by formula (I), a pharmaceutically acceptable salt of same, or an isomer thereof.
    Type: Application
    Filed: January 22, 2020
    Publication date: February 23, 2023
    Inventors: Xile LIU, Charles Z. DING, Shuhui CHEN, Lihong HU, Haiwen WAN
  • BIARYL COMPOUND AS PAN-RAF KINASE INHIBITOR
    Publication number: 20230046018
    Abstract: Disclosed is a biarylamide compound as a Pan-RAF kinase inhibitor, and specifically disclosed are a compound as shown in formula (III) and a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: December 4, 2020
    Publication date: February 16, 2023
    Inventors: Charles Z. DING, Xile LIU, Shuhui CHEN, Lihong HU, Chengliang ZHOU
  • Pyrimidine compound acting on EGFR and ERBB2
    Patent number: 11530196
    Abstract: Disclosed is a pyrimidine compound acting on an EGFR exon 20 insertion mutation and an ERBB2 exon 20 insertion mutation or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: July 24, 2020
    Date of Patent: December 20, 2022
    Assignee: CHINA RESOURCES PHARMACEUTICAL HOLDINGS COMPANY LIMITED
    Inventors: Charles Z. Ding, Lu Zhang, Xile Liu, Lihong Hu, Wen Jiang, Jian Li, Shuhui Chen
  • PYRIMIDINE COMPOUND ACTING ON EGFR AND ERBB2
    Publication number: 20220289714
    Abstract: Disclosed is a pyrimidine compound acting on an EGFR exon 20 insertion mutation and an ERBB2 exon 20 insertion mutation or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: July 24, 2020
    Publication date: September 15, 2022
    Inventors: Charles Z. DING, Lu ZHANG, Xile LIU, Lihong HU, Wen JIANG, Jian LI, Shuhui CHEN
  • Aryl-phosphorus-oxygen compound as EGFR kinase inhibitor
    Patent number: 11390625
    Abstract: Disclosed is a class of new aryl-phosphorus-oxygen compounds as shown in formula (I) as EGFR kinase inhibitors, and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: July 19, 2018
    Date of Patent: July 19, 2022
    Assignee: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.
    Inventors: Lingyun Wu, Xile Liu, Charles Z. Ding, Shuhui Chen, Lihong Hu, Lele Zhao, Wei Pan, Guoping Hu, Jian Li, Ning Zhao, Jun Zhao
  • CRYSTAL FORM OF EGFR INHIBITOR AND PREPARATION METHOD THEREOF
    Publication number: 20220194959
    Abstract: Disclosed are a crystal form of an EGFR inhibitor and a preparation method thereof. Further disclosed is an application of the crystal form in preparing a drug for treating non-small cell lung cancer, especially an application in preparing a drug for treating non-small cell lung cancer with brain metastases.
    Type: Application
    Filed: April 10, 2020
    Publication date: June 23, 2022
    Applicant: MEDSHINE DISCOVERY INC.
    Inventors: Xile LIU, Lu ZHANG, Charles Z. DING, Shuhui CHEN, Lihong HU
  • SALT OF EGFR INHIBITOR, CRYSTAL FORM, AND PREPARATION METHOD THEREFOR
    Publication number: 20220119431
    Abstract: Provided are a salt of an EGFR inhibitor, a crystal form thereof and a preparation method therefor, and an application of the salt and the crystal form in the preparation of a treatment for non-small cell lung cancer. The salt has a structure as shown in formula (II).
    Type: Application
    Filed: January 17, 2020
    Publication date: April 21, 2022
    Inventors: Lingyun WU, Xile LIU, Charles Z. DING, Shuhui CHEN, Lihong HU, Lele ZHAO, Wei PAN, Guoping HU, Jian LI, Ning ZHAO, Jun ZHAO
  • Quinazoline compound for EGFR inhibition
    Patent number: 11040984
    Abstract: Disclosed is a novel quinazoline compound. Specifically, disclosed are a compound represented by the formula (I) and a pharmacologically acceptable salt.
    Type: Grant
    Filed: December 29, 2017
    Date of Patent: June 22, 2021
    Assignee: MEDSHINE DISCOVERY INC.
    Inventors: Xile Liu, Charles Z. Ding, Shuhui Chen, Lingyun Wu, Lihong Hu, Haiwen Wan
  • Aryl-Phosphorus-Oxygen Compound As EGFR Kinase Inhibitor
    Publication number: 20200207768
    Abstract: Disclosed is a class of new aryl-phosphorus-oxygen compounds as shown in formula (I) as EGFR kinase inhibitors, and pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: July 19, 2018
    Publication date: July 2, 2020
    Inventors: Lingyun WU, Xile LIU, Charles Z. DING, Shuhui CHEN, Lihong HU, Lele ZHAO, Wei PAN, Guoping HU, Jian LI, Ning ZHAO, Jun ZHAO
  • QUINAZOLINE COMPOUND FOR EGFR INHIBITION
    Publication number: 20200190107
    Abstract: Disclosed is a novel quinazoline compound. Specifically, disclosed are a compound represented by the formula (I) and a pharmacologically acceptable salt.
    Type: Application
    Filed: December 29, 2017
    Publication date: June 18, 2020
    Inventors: Xile LIU, Charles Z. DING, Shuhui CHEN, Lingyun WU, Lihong HU, Haiwen WAN
  • Fused-ring or tricyclic aryl pyrimidine compound used as kinase inhibitor
    Patent number: 10494373
    Abstract: Disclosed is a fused-ring or tricyclic aryl pyrimidine compound used as a mutation selectivity EGFR inhibitor. Specifically, disclosed is a compound represented by formula (I) and used as an EGFR inhibitor or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: April 20, 2016
    Date of Patent: December 3, 2019
    Assignee: Guangdong Zhongsheng Pharmaceutical Co., Ltd
    Inventors: Charles Z. Ding, Shuhui Chen, Baoping Zhao, Xile Liu, Linxia Xiao, Chao Ding, Fei Wang, Jian Li
  • FUSED-RING OR TRICYCLIC ARYL PYRIMIDINE COMPOUND USED AS KINASE INHIBITOR
    Publication number: 20180354953
    Abstract: Disclosed is a fused-ring or tricyclic aryl pyrimidine compound used as a mutation selectivity EGFR inhibitor. Specifically, disclosed is a compound represented by formula (I) and used as an EGFR inhibitor or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: April 20, 2016
    Publication date: December 13, 2018
    Inventors: Charles Z. DING, Shuhui CHEN, Baoping ZHAO, Xile LIU, Linxia XIAO, Chao DING, Fei WANG, Jian LI
  • Fused-ring or tricyclic aryl pyrimidine compound used as kinase inhibitor
    Patent number: 10093656
    Abstract: Disclosed is a fused-ring or tricyclic aryl pyrimidine compound used as a mutation selectivity EGFR inhibitor. Specifically, disclosed is a compound represented by formula (I) and used as an EGFR inhibitor or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: November 14, 2017
    Date of Patent: October 9, 2018
    Assignee: NANJING SANHOME PHARMACEUTICAL CO., LTD
    Inventors: Charles Z. Ding, Shuhui Chen, Baoping Zhao, Xile Liu, Linxia Xiao, Chao Ding, Fei Wang, Jian Li
  • Spirocyclic aryl phosphorus oxide and aryl phosphorus sulfide
    Patent number: 10053477
    Abstract: Disclosed is a spirocyclic aryl phosphorus oxide or sulfide as an ALK inhibitor, particularly, a compound represented by formula (I) as an ALK inhibitor or pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: June 29, 2015
    Date of Patent: August 21, 2018
    Assignee: QILU PHARMACEUTICAL CO., LTD.
    Inventors: Zhaozhong Ding, Minghui Zhang, Shuhui Chen, Xile Liu, Yidong Zhu, Chuanwen Fan, Baoping Zhao, Long Zhang, Yingying Yang, Qingmei Zheng, Shansong Zheng, Haiwen Wan, Jinqing Hu
  • Fused-Ring Or Tricyclic Aryl Pyrimidine Compound Used As Kinase Inhibitor
    Publication number: 20180072704
    Abstract: Disclosed is a fused-ring or tricyclic aryl pyrimidine compound used as a mutation selectivity EGFR inhibitor. Specifically, disclosed is a compound represented by formula (I) and used as an EGFR inhibitor or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: November 14, 2017
    Publication date: March 15, 2018
    Inventors: Charles Z. DING, Shuhui CHEN, Baoping ZHAO, Xile LIU, Linxia XIAO, Chao DING, Fei WANG, Jian LI
  • SPIROCYCLIC ARYL PHOSPHORUS OXIDE AND ARYL PHOSPHORUS SULFIDE
    Publication number: 20170129909
    Abstract: Disclosed is a spirocyclic aryl phosphorus oxide or sulfide as an ALK inhibitor, particularly, a compound represented by formula (I) as an ALK inhibitor or pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: June 29, 2015
    Publication date: May 11, 2017
    Applicant: QUILU PHARMACEUTICAL CO., LTD.
    Inventors: Zhaozhong DING, Minghui ZHANG, Shuhui CHEN, Xile LIU, Yidong ZHU, Chuanwen FAN, Baoping ZHAO, Long ZHANG, Yingying YANG, Qingmei ZHENG, Shansong ZHENG, Haiwen WAN, Jinqing HU